Endoscopic mapping and surrogate markers for better surveillance in Barrett esophagus - A study of 700 biopsy specimens

被引:16
作者
Bhargava, P
Eisen, GM
Holterman, DA
Azumi, N
Hartmann, DP
Hanfelt, JJ
Benjamin, SB
Lippman, ME
Montgomery, EA
机构
[1] Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA
[2] Georgetown Univ, Dept Gastroenterol, Washington, DC 20007 USA
[3] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
关键词
Barrett; p53; DNA ploidy; Ki-67; PCNA; c-erbB-2; bcl-2; MIB-1; endoscopic mapping; prospective; markers;
D O I
10.1309/93WG-ERRB-PN57-C15A
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Surveillance methods in Barrett esophagus (BE) using light microscopic examination of random biopsy specimens may miss focal dysplasia. In addition, dysplastic foci identified initially may not be relocated subsequently, making chemoprevention studies difficult. By using a special gastroscope, systematic mapping (4-quadrant biopsy specimens at 1-cm intervals) was performed in 22 patients (33 total mappings yielding 700 biopsy specimens). H&E, immunohistochemistry, and DNA ploidy analysis were performed. c-erbB-2 and positive Ki-67 were detected only in dysplastic sites; thus, their detection did not precede morphologically identifiable dysplasia. On the other hand aneuploidy and p53 were detected in dysplastic and nondysplastic areas. p53 was correlated with dysplasia, and S-phase narrowly missed correlation, while aneuploidy was not correlated. PCNA and bcl-2 were ubiquitous, limiting their usefulness. On second maps, epithelial type was reidentified with 81% accuracy. A significant correlation was found between p53 and dysplasia. Sites of dysplasia and abnormal biomarkers could be relocated accurately by using endoscopic mapping. Therefore, mapping combined with biomarker studies may provide better surveillance and serve as a useful technique in chemoprevention studies.
引用
收藏
页码:552 / 563
页数:12
相关论文
共 69 条
[1]  
[Anonymous], 1990, HISTOLOGICAL TYPING
[2]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[3]   BARRETTS-ESOPHAGUS - RESULTS OF A MULTICENTRIC SURVEY [J].
BONELLI, L .
ENDOSCOPY, 1993, 25 (09) :652-654
[4]   BARRETT-ESOPHAGUS AND ADENOCARCINOMA - FROM THE FAMILY TO THE GENE [J].
CAMERON, AJ .
GASTROENTEROLOGY, 1992, 102 (04) :1421-1424
[5]   THE INCIDENCE OF ADENOCARCINOMA IN COLUMNAR-LINED (BARRETTS) ESOPHAGUS [J].
CAMERON, AJ ;
OTT, BJ ;
PAYNE, WS .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (14) :857-859
[6]   CLINICAL IMPLICATIONS OF P53 GENE MUTATION IN THE PROGRESSION OF BARRETTS EPITHELIUM TO INVASIVE ESOPHAGEAL CANCER [J].
CASSON, AG ;
MANOLOPOULOS, B ;
TROSTER, M ;
KERKVLIET, N ;
OMALLEY, F ;
INCULET, R ;
FINLEY, R ;
ROTH, JA .
AMERICAN JOURNAL OF SURGERY, 1994, 167 (01) :52-57
[7]   Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis [J].
Cawley, HM ;
Meltzer, SJ ;
De Benedetti, VMG ;
Hollstein, MC ;
Muehlbauer, KR ;
Liang, L ;
Bennett, WP ;
Souza, RF ;
Greenwald, BD ;
Cottrell, J ;
Salabes, A ;
Bartsch, H ;
Trivers, GE .
GASTROENTEROLOGY, 1998, 115 (01) :19-27
[8]  
Coggi G, 1997, CANCER, V79, P425, DOI 10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO
[9]  
2-H
[10]  
Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO